FDA approves Lilly's new Alzheimer's drug after delay

The Food and Drug Administration (FDA) on Tuesday approved Eli Lilly’s Alzheimer’s drug, the company announced, clearing the way for another entry into the market of a new class of drugs that moderately slows the disease’s progression. 

The agency last month held an advisory panel meeting to scrutinize the safety and effectiveness of the drug, called donanemab, after delaying approval in March.  

The decision to require a panel meeting came as a surprise to the company, which...